DelveInsight launched a new report on ‘Alport Syndrome – Epidemiology Forecast to 2030’.
DelveInsight’s ‘Alport Syndrome – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Alport Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the facts of the report
1. Alport syndrome occurs in approximately 1 in 50,000 newborns. 2. Alport syndrome is estimated to account for 3% of children with chronic kidney disease and 0.2% of adults with end-stage renal disease in the United States. 3. Alport Syndrome is estimated to affect approximately 1 in 5,000-10,000 people in the general population in the United States.
“According to DelveInsight, Alport syndrome primarily affects men.” Alport Syndrome (also referred to as hereditary nephritis) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities. Patients with Alport Syndrome will experience progressive loss of kidney function. Almost all patients experience blood in their urine (hematuria) as well as proteinuria at symptom onset. The kidneys lose function as this condition progresses, resulting in kidney failure. There are three genetic Sub-divisions. X-linked Alport Syndrome (XLAS) is the most common; in these families affected males typically have more severe disease than affected females.
In autosomal recessive Alport Syndrome (ARAS) the severity of disease in affected males and females is similar. There is also an autosomal dominant form (ADAS) that affects males and females with equal severity. Alport Syndrome is caused by mutations in specific genes.
People with Alport Syndrome frequently develop sensor neural hearing loss, which is caused by abnormalities of the inner ear, during late childhood or early adolescence. Affected individuals may also have misshapen lenses in the eyes (anterior lenticonus) and abnormal coloration of the light- sensitive tissue at the back of the eye (retina). These eye abnormalities seldom lead to vision loss.
“According to DelveInsight, Significant hearing loss, eye abnormalities, and progressive kidney disease are more common in males with Alport Syndrome than in affected females. “
Request for sample pages : https://www.delveinsight.com/sample-request/alport-syndrome-epidemiology-forecast
Scope of the Report
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
Reasons to buy
Key Assessments
Related Reports:
Alport Syndrome – Pipeline Insights, 2020
The Alport Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alport Syndrome across the complete product development cycle, including all clinical and nonclinical stages.
Alport Syndrome – Market Insights, Epidemiology, and Market Forecast-2030
The Alport Syndrome market report provides current treatment practices, emerging drugs, Alport Syndrome market share of the individual therapies, current and forecasted Alport Syndrome market Size from 2017 to 2030 segmented by seven major markets.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/